Target intelligence / Profile preview

D-alanyl-D-alanine terminus of cell wall precursor unit

Molecular classification
Other (cell wall precursor motif), Not a protein, but a structural motif in peptidoglycan biosynthesis
01

Overview

The D-alanyl-D-alanine terminus of cell wall precursor units is a critical structural motif found at the end of the peptide side chains in bacterial peptidoglycan precursors. This dipeptide sequence forms part of the pentapeptide stem attached to N-acetylmuramic acid residues within peptidoglycan, which provides mechanical strength and rigidity to bacterial cell walls. The synthesis involves enzymes such as D-Ala–D-Ala ligase (ddlA) that catalyze formation of this dipeptide from two molecules of D-alanine. The terminal D-Ala–D-Ala serves as a substrate for transpeptidases during cross-linking reactions that stabilize the mature cell wall. This site is also an important therapeutic target because several classes of antibiotics exploit its unique presence in bacteria. Glycopeptides like vancomycin bind directly to this moiety, preventing proper cross-linking by sterically hindering access by transglycosylases and transpeptidases. β-Lactam antibiotics act indirectly by mimicking this structure, thereby inhibiting penicillin-binding proteins involved in cross-linking. Resistance can arise when bacteria replace one or both terminal alanines with other amino acids such as lactate or serine, reducing drug binding affinity. This molecular feature does not exist in mammalian cells—making it an ideal selective antibacterial target with minimal risk for direct toxicity to human tissues.

Other names
D-Ala-D-Ala terminusD-alanyl-D-alanine dipeptidePeptidoglycan pentapeptide C-terminal dipeptide
02

Mechanism of action

Glycopeptide antibiotics (e.g., vancomycin) bind directly to the D-alanyl-D-alanine terminus, blocking transpeptidation and transglycosylation steps required for cross-linking peptidoglycan strands.

03

Biological functions

Cell wall biosynthesisMaintenance of cell shape and integrity in bacteriaTarget for antibiotic action (e.g., β-lactams, glycopeptides)
04

Disease associations

Infection (as the target is essential for bacterial viability and thus relevant to infectious diseases)
05

Safety considerations

null (the target itself is not present in humans; safety concerns relate to off-target effects or resistance mechanisms rather than direct targeting)
06

Interacting drugs

Vancomycin

4 more in the full profile.

Beyond the preview

Go deeper on D-alanyl-D-alanine terminus of cell wall precursor unit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-alanyl-D-alanine terminus of cell wall precursor unit.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call